Mylan launches generic version of seizure injections
Essential IR Insights Newsletter Fall - 2023
A Corporation Clearly Pinpoints Activist Investor Activity
Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise
Insight Weekly: US companies boost liquidity; auto insurers hike rates; office sector risk rises
Mylan NV launched a generic version of Pfizer Inc.'s Cerebyx injection in the U.S.
The fosphenytoin sodium injections will be available in single-use vials for the treatment of certain types of seizures.
The treatment had U.S. sales of approximately $36.3 million for the 12 months ending Oct. 31, according to IMS Health.
